Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies

Eugenie AMT Obbens, Lynn G. Feun, Milam E. Leavens, Niramol Savaraj, David J. Stewart, Jordan U. Gutterman

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Eight patients were treated with leukocyte interferon for a variety of neurological malignancies that had failed or recurred after conventional therapy. Three patients with malignant astrocytoma received intratumoral interferon in dosages up to 9 million units 3×/ week, with total dosages of up to 160 million units. Interferon was administered intraventricularly in 4 patients with leptomeningeal metastases and one patient with multiple brain metastases. Dosages increased from 1 to 10 million units 3×/ week, and total dosages of up to 113 million units were given intraventricularly. Acute side effects of fever, nausea, vomiting, and headache occurred almost exclusively with intraventricular injections, and these subsided after the initial injection. Fatigue, loss of appetite, weight loss, and hematologic toxicity developed a few weeks after onset of treatment, independent of the dose given. A modest tumor regression was seen on CT scans of one patient with a malignant astrocytoma, who was treated with interferon for 8 months. In a114 patients with leptomeningeal metastases, the CS F became free of malignant cells for 6 to 10 weeks, while clinical improvement was less dramatic.

Original languageEnglish (US)
Pages (from-to)61-67
Number of pages7
JournalJournal of neuro-oncology
Volume3
Issue number1
DOIs
StatePublished - Mar 1 1985
Externally publishedYes

Keywords

  • interferon
  • intratumoral treatment
  • intraventricular treatment
  • leptomeningeal metastases
  • malignant gliomas

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies'. Together they form a unique fingerprint.

  • Cite this